NYSE:ABBV (AbbVie)
About ABBV
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
AbbVie (NYSE: ABBV) Latest News
![The flag of the United States of America flying in front of the Capitol building](https://www.fool.co.uk/wp-content/uploads/2022/10/US-flag-400x225.jpg)
Investing Articles
3 top US dividend stocks for value investors to consider in 2024
![The flag of the United States of America flying in front of the Capitol building](https://www.fool.co.uk/wp-content/uploads/2022/10/US-flag-400x225.jpg)
Investing Articles
2 great dividend shares I’m buying now
![The flag of the United States of America flying in front of the Capitol building](https://www.fool.co.uk/wp-content/uploads/2022/10/US-flag-400x225.jpg)
Investing Articles
2 great dividend shares I’m buying now
Investing Articles
3 pharma stocks to watch in April
Investing Articles
Should I Invest In Direct Line Insurance Group PLC, Mountview Estates plc And Shire PLC Now?
Investing Articles
Is Shire PLC A Buy After AbbVie Inc Withdraws Takeover Offer?
Investing Videos
A Closer Look At Shire PLC
Investing Articles
Why AbbVie Inc Is Buying Shire PLC
Company Comment
Shire PLC Accepts £32bn Takeover By AbbVie Inc
Investing Articles
One Reason Why AstraZeneca plc Is A Risky Bet
Company Comment
Shire PLC Willing To Recommend £32bn Bid From AbbVie Inc
Investing Articles
AbbVie Inc’s Raised Bid Confirms My Shire PLC Sell Rating
1❯